A group of Mexican entrepreneurs created a ‘bio-skin’ based on polysaccharides or sugars obtained from the blue agave bagasse to treat second and third degree burns that facilitate the healing process.
Michael Sullivan Barrera, commercial director of the innovative company Bioimplants, explained that agave was chosen due to its characteristics, such as the resistance to high temperatures at the moment of subjecting the product to sterilization and its sugars’ natural ability of maintaining the humidity in the plant, which is endemic to arid zones. Additionally, this plant presents the properties required for the treatment of this type of wounds.
Regarding the manufacture of the patches, Sullivan Barrera said that from a quarter of the heart (piña) of the plant a thousand dermal implants of five by seven centimeters can be obtained. For this, the raw material is reduced to a gel, and then subjected to dehydration by lyophilization. Through this process micro-porous flesh-colored material is obtained which can be molded as desired.
“They are designed as sheets of five by seven centimeters; however, depending on the size of the wound, they can be joined one by one and adjusted as desired,” said Sullivan Barrera.
The patches prevent dehydration of the skin caused by burn and are designed for people with second and third degree wounds, which are the most serious. It should be noted that the silicone is automatically released on day 18 after placement, while mesh becomes part of the skin.
When there is damage in deep skin layers, the organism cannot form scar tissue because it does not have a structure for the cells to grow and form the skin again. “The human body only requires a type of ‘scaffold’ for the cells to stick to it, our implants provide that support,” he said.
The bio-skin is in the process of obtaining a patent and has already been tested with animals with promising results. Currently the researchers are seeking to obtain permission by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) to start clinical trials.
Source: La Jornada